Related Experiment Videos
Photopheresis for T cell mediated diseases
1Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
Advances in Dermatology
|January 1, 1988
Summary
Photopheresis offers a safe method for immunomodulation via extracorporeal drug activation. This approach is effective for erythrodermic cutaneous T-cell lymphoma and shows promise for other immune-related diseases.
Area of Science:
- Dermatology
- Immunology
- Photobiology
Background:
- Photopheresis is a safe and simple immunomodulatory treatment.
- Extracorporeal drug activation using UVA represents a novel drug delivery method.
- Its efficacy is recognized in erythrodermic cutaneous T-cell lymphoma (CTCL).
Purpose of the Study:
- To highlight photopheresis as a method for controlled, extracorporeal immunomodulation.
- To discuss its established role in treating erythrodermic CTCL.
- To propose its potential application in other immune-mediated diseases.
Main Methods:
- Utilizes extracorporeal activation of a drug with UVA radiation.
- Involves performing immunomodulating therapy outside the patient's body.
- Allows for controlled cellular manipulation under ex vivo conditions.
Main Results:
- Demonstrates the established usefulness of photopheresis in erythrodermic CTCL.
- Confirms photopheresis as a safe and technically simple immunomodulatory modality.
- Highlights the controlled environment for cellular manipulation outside the host.
Conclusions:
- Photopheresis is a viable and safe immunomodulatory therapy.
- The system serves as a paradigm for future immunomodulatory treatments.
- Potential applications include pemphigus vulgaris and lupus erythematosus.